Project Grant R01AI195887
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $829K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $785,998 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how protease allergen exposure induces metabolic and mitochondrial remodeling in sensory neurons that amplifies immune response upon re-exposure. The research addresses allergic disease initiation mechanisms in a population where allergic diseases affect nearly half of the United States...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $776,034 on February 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode the neuroimmune control of cutaneous gamma-delta T cell function in allergic immunity. The research investigates a bidirectional neuroimmune circuit involving sensory neurons and epidermal gamma-delta T cells (GD3S) in allergic skin responses. The study integrates cellular immunology,...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $216,098 on May 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support mentoring and patient-oriented research into environmental and microbiome influences on respiratory health. Dr. Peggy Lai's research program examines how environmental exposures, particularly indoor humidity, modulate the virome and microbiome to influence allergic and infectious lung disease...
- The National Institute of Allergy and Infectious Diseases awarded Massachusetts General Hospital $747,953 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for investigator-initiated research on lung-resident memory TH2 cells in asthma. The project, R01AI192629, identifies pathways that mediate survival and maintenance of allergen-specific tissue-resident memory TH2 cells in specialized niches within the asthmatic lung. The research focuses on the CXCR6...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $453,750 on June 17, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an innovative high-throughput airway organoid screening platform. This research project, scheduled for completion by May 31, 2027, focuses on identifying novel mechanisms of communication between airway epithelial cells (AECs) and intraepithelial...
- The National Institute of Allergy and Infectious Diseases awarded the University of Massachusetts Medical School $836,691 on June 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate nonlinear complex dynamics of tuft cell-microbiota cross-talk and feedback loops regulating intestinal immune responses and microbial modulation. The project combines mathematical modeling and experimental validation to characterize how tuft cells sense microbial...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital a $453,750 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, through July 31, 2027. The award funds research investigating neutrophil swarming mechanisms in response to Pseudomonas aeruginosa microcolony aggregates. The research will develop an ex vivo model to elucidate the cellular and molecular...
- The National Institute of Allergy and Infectious Diseases awarded $3,080,416 to Brigham & Women's Hospital Inc. on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate T Helper 2 memory cell populations in chronic type 2 inflammation. The research defines the factors that sustain tissue TH2 multipotent progenitor (TH2-MPP) populations, a progenitor-like T cell population identified in human disease tissue that drives pathology through...
- The National Institute of Allergy and Infectious Diseases awarded $436,454 to Massachusetts General Hospital on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate gastrointestinal tract-driven T cell reprogramming during acute graft-versus-host disease (AGVHD). The recipient will conduct research across three specific aims examining how the gastrointestinal tract drives systemic alloimmunity in patients after allogeneic hematopoietic cell...
- Federal Grant Award Summary Award Details: Massachusetts General Hospital (The General Hospital Corporation) received a $250,000 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 1, 2025, with completion anticipated July 31, 2026. Research Objectives and Deliverables: This grant supports biomedical research investigating lung-resident memory T helper type 2 (TH2) cells as novel...